Ignite Creation Date:
2025-12-24 @ 9:57 PM
Ignite Modification Date:
2026-03-08 @ 12:50 AM
Study NCT ID:
NCT05429632
Status:
RECRUITING
Last Update Posted:
2025-12-05
First Post:
2022-06-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Sponsor:
Priothera SAS
Organization:
Study Overview
Official Title:
Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT
Status:
RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MO-TRANS
Brief Summary:
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Detailed Description:
The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT).
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: